HC Wainwright set a $75.00 price objective on Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Wednesday, January 3rd. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts have also recently weighed in on the stock. Oppenheimer reissued a buy rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. UBS Group reissued an outperform rating and issued a $56.51 price target (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. BidaskClub raised shares of Sarepta Therapeutics from a hold rating to a buy rating in a research report on Monday, December 25th. Zacks Investment Research cut shares of Sarepta Therapeutics from a buy rating to a hold rating in a research report on Friday, December 15th. Finally, Needham & Company LLC reissued a buy rating on shares of Sarepta Therapeutics in a research report on Friday, October 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the stock. Sarepta Therapeutics presently has an average rating of Buy and an average target price of $64.65.
Sarepta Therapeutics (NASDAQ:SRPT) traded down $0.03 during trading on Wednesday, hitting $67.58. 1,291,118 shares of the stock traded hands, compared to its average volume of 1,740,000. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $68.90. The stock has a market cap of $4,370.00, a PE ratio of -33.13 and a beta of 1.37. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The firm had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the previous year, the company earned ($0.95) earnings per share. sell-side analysts expect that Sarepta Therapeutics will post -3.07 earnings per share for the current year.
In other news, SVP Shamim Ruff sold 10,000 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 4.0% during the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after acquiring an additional 162,543 shares during the period. HealthCor Management L.P. increased its stake in shares of Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares during the period. Jennison Associates LLC increased its stake in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the period. Eagle Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 26.0% during the third quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after acquiring an additional 207,810 shares during the period. Finally, Emerald Advisers Inc. PA increased its stake in shares of Sarepta Therapeutics by 2.1% during the third quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after acquiring an additional 18,077 shares during the period. Institutional investors and hedge funds own 81.97% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/28/hc-wainwright-reiterates-75-00-price-target-for-sarepta-therapeutics-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.